Logo
x

Search category

Subscribe Now

Biocon

Biocon Reports P-I Study (RHINE-3) Results of Biosimilar Insulin

Biocon Reports P-I Study (RHINE-3) Results of Biosimilar Insulin

  • December 25, 2022
Biocon Entered into an Out-Licensing Agreement with Yoshindo to Commercialize bUstekinumab and bDenosumab in the Japan

Biocon Entered into an Out-Licensing Agreement with Yoshindo to Commercialize bUstekinumab and bDenosumab in the Japan

  • October 17, 2022
Biocon to Acquire Viatris’ Biosimilars Assets for ~$3.335B

Biocon to Acquire Viatris’ Biosimilars Assets for ~$3.335B

  • March 1, 2022
Biocon’s Insulin-R Demonstrated Pharmacokinetic and Pharmacodynamic Equivalence to Eli Lilly’s Humulin-R

Biocon’s Insulin-R Demonstrated Pharmacokinetic and Pharmacodynamic Equivalence to Eli Lilly’s Humulin-R

  • January 17, 2022
PharmaShots Weekly Snapshots (November 15 - 19, 2021)

PharmaShots Weekly Snapshots (November 15 - 19, 2021)

  • November 19, 2021
Top 20 Generics Pharma Companies Based On 2020 Revenue

Top 20 Generics Pharma Companies Based On 2020 Revenue

  • October 28, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.